Skip to content

Released Nov 14, 2022, after the close

10-Q filed Nov 14, 2022, 45 days after period end · 0001493152-22-032117

Q2 2023 · 10-Q
Revenue$8.59M+0.3% vs Q2 2022+11.9% vs Q1 2023
Net Income$1.52M−15.7% vs Q2 2022+395.3% vs Q1 2023
EPS Diluted$0.00— vs Q2 2022no prior Q1 2023 on file
Gross Profit$3,824,434+1.5%
Operating Income$1,081,117−24.0%
Operating Cash Flowderived$1,495,414+872.4%
Free Cash Flowderived-$3,609,685—
Margins · derived
Gross margin44.5%+0.5 pt vs Q2 2022
Operating margin12.6%−4.0 pt vs Q2 2022
Net margin17.6%−3.3 pt vs Q2 2022

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2023Q2 2022Q2 2021Q2 2020
Revenue$8.59M$8.56M$7.40M$4.63M
Net Income$1.52M$1.80M$2.48M-$1.60M
EPS Diluted$0.00$0.00$0.00$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Elite Pharmaceuticals Inc · CIK 1053369 · Engraved from SEC EDGAR